-
Miner P Jr, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, pantoprazole and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003;98:2616–20.
-
Miner P, Katz P, Chen Y, Sostek M. Reanalysis of intragastric pH results based on updated correction factors for slimline and zinetics 24 single-use pH catheters. Am J Gastroenterol 2006;101:404–5, 406.
-
Röhss K, Wilder-Smith C, Nauclér E, Jansson L. Esomeprazole 20 mg provides more effective intragastric acid control than maintenance-dose rabeprazole, lansoprazole or pantoprazole in healthy volunteers. Clin Drug Invest 2004;24:1–7
-
Kahrilas P, Falk G, Johnson D, Schmitt C, Collins D, Whipple J, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux esophagitis patients: a randomized controlled trial. Aliment Pharmacol Ther 2000;14:1249–58.
-
Richter J, Kahrilas J, Johanson J, Maton P, Breiter J, Hwang C, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001;96:656–65.
-
Castell D, Kahrilas P, Richter J, Vakil N, Johnson D, Zuckerman S, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002;97:575–83
-
Labenz J, Armstrong D, Lauritsen K, Katelaris P, Schmidt S, Schütze K et al. A randomised comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive esophagitis: the EXPO study. Aliment Pharmacol Ther 2005;21:739–46.
-
Labenz J, Armstrong D, Lauritsen K, Katelaris P, Schmidt S, Schütze K et al. Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study. Aliment Pharmacol Ther 2005;22:803–11.
-
Lauritsen K, Devière J, Bigard M-A, Bayerdörffer E, Mózsik G, Murray F, et al. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux esophagitis: Metropole study results. Aliment Pharmacol Ther 2003;17:333–41.
-
Vakil NB, Shaker R, Johnson DA, Kovacs T, Baerg RD, Hwang C et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive esophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001;15:926–35.
-
Scheiman JM, Yeomans ND, Talley NJ, Vakil NB, Chan FK, Tulassay Z et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006;101:1–10.